4//SEC Filing
Mitchell Stephen Ray 4
Accession 0001209191-21-055685
CIK 0001347178other
Filed
Sep 12, 8:00 PM ET
Accepted
Sep 13, 4:40 PM ET
Size
13.2 KB
Accession
0001209191-21-055685
Insider Transaction Report
Form 4
Mitchell Stephen Ray
Director
Transactions
- Sale
Common Stock
2021-09-09$16.74/sh−19,109$319,976→ 9,215 total - Exercise/Conversion
Stock Option (right to buy)
2021-09-09−13,124→ 21,876 totalExercise: $12.70Exp: 2030-02-13→ Common Stock (13,124 underlying) - Exercise/Conversion
Common Stock
2021-09-09$10.57/sh+5,985$63,261→ 15,200 total - Exercise/Conversion
Stock Option (right to buy)
2021-09-09−5,985→ 0 totalExercise: $10.57Exp: 2030-06-10→ Common Stock (5,985 underlying) - Exercise/Conversion
Common Stock
2021-09-09$12.70/sh+13,124$166,675→ 28,324 total
Footnotes (4)
- [F1]A portion of the shares was sold to satisfy the exercise price of the stock options.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.53 to $16.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- [F3]This option vested and became exercisable with respect to 100% of the option shares on June 11, 2021.
- [F4]The option vested with respect to 25% of the underlying shares on February 14, 2021, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date.
Documents
Issuer
Vanda Pharmaceuticals Inc.
CIK 0001347178
Entity typeother
Related Parties
1- filerCIK 0001802653
Filing Metadata
- Form type
- 4
- Filed
- Sep 12, 8:00 PM ET
- Accepted
- Sep 13, 4:40 PM ET
- Size
- 13.2 KB